NASDAQ:KRRO Korro Bio (KRRO) Stock Price, News & Analysis $12.42 -0.40 (-3.12%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$12.57 +0.15 (+1.21%) As of 05/28/2025 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Korro Bio Stock (NASDAQ:KRRO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Korro Bio alerts:Sign Up Key Stats Today's Range$12.26▼$13.1650-Day Range$12.42▼$24.0352-Week Range$11.13▼$98.00Volume91,326 shsAverage Volume99,486 shsMarket Capitalization$116.64 millionP/E RatioN/ADividend YieldN/APrice Target$102.43Consensus RatingBuy Company OverviewKorro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Read More… Korro Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreKRRO MarketRank™: Korro Bio scored higher than 42% of companies evaluated by MarketBeat, and ranked 692nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingKorro Bio has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKorro Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Korro Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Korro Bio are expected to decrease in the coming year, from ($9.52) to ($10.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Korro Bio is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Korro Bio is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKorro Bio has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Korro Bio's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.49% of the float of Korro Bio has been sold short.Short Interest Ratio / Days to CoverKorro Bio has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.Change versus previous monthShort interest in Korro Bio has recently increased by 0.94%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKorro Bio does not currently pay a dividend.Dividend GrowthKorro Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.49% of the float of Korro Bio has been sold short.Short Interest Ratio / Days to CoverKorro Bio has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.Change versus previous monthShort interest in Korro Bio has recently increased by 0.94%, indicating that investor sentiment is decreasing. News and Social Media2.2 / 5News Sentiment0.96 News SentimentKorro Bio has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Korro Bio this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Korro Bio to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Korro Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Korro Bio is held by insiders.Percentage Held by InstitutionsOnly 13.18% of the stock of Korro Bio is held by institutions.Read more about Korro Bio's insider trading history. Receive KRRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Korro Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address KRRO Stock News HeadlinesFY2025 EPS Forecast for Korro Bio Decreased by AnalystMay 19, 2025 | americanbankingnews.comKorro to Participate in Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.May 29, 2025 | Colonial Metals (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Veracyte (VCYT), Schrodinger (SDGR) and Korro Bio (KRRO)May 14, 2025 | theglobeandmail.comKorro Bio to Cut 20% of WorkforceMay 7, 2025 | marketwatch.comKorro Bio to Cut 20% of WorkforceMay 7, 2025 | marketwatch.comKorro Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 7, 2025 | globenewswire.comCantor Fitzgerald Initiates Coverage of Korro Bio (KRRO) with Overweight RecommendationApril 30, 2025 | msn.comSee More Headlines KRRO Stock Analysis - Frequently Asked Questions How have KRRO shares performed this year? Korro Bio's stock was trading at $38.07 at the beginning of the year. Since then, KRRO stock has decreased by 67.4% and is now trading at $12.42. View the best growth stocks for 2025 here. How were Korro Bio's earnings last quarter? Korro Bio, Inc. (NASDAQ:KRRO) released its earnings results on Wednesday, May, 7th. The company reported ($2.49) EPS for the quarter, topping analysts' consensus estimates of ($2.60) by $0.11. The business earned $2.55 million during the quarter, compared to the consensus estimate of $0.13 million. Who are Korro Bio's major shareholders? Korro Bio's top institutional shareholders include Driehaus Capital Management LLC (6.20%), Cormorant Asset Management LP (4.05%), Tri Locum Partners LP (1.37%) and Aberdeen Group plc (0.90%). Insiders that own company stock include Venture Opportunity Fund Atlas, David L Lucchino and Vineet Agarwal. View institutional ownership trends. How do I buy shares of Korro Bio? Shares of KRRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Korro Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Korro Bio investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/07/2025Today5/28/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRRO Previous SymbolNASDAQ:KRRO CIK1703647 Webwww.frequencytx.com Phone781-315-4600FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Stock Price Target$102.43 High Stock Price Target$180.00 Low Stock Price Target$25.00 Potential Upside/Downside+724.7%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($9.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$81.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-50.25% Return on Assets-38.48% Debt Debt-to-Equity RatioN/A Current Ratio11.23 Quick Ratio11.23 Sales & Book Value Annual Sales$4.82 million Price / Sales24.19 Cash FlowN/A Price / Cash FlowN/A Book Value$21.19 per share Price / Book0.59Miscellaneous Outstanding Shares9,391,000Free Float8,862,000Market Cap$116.64 million OptionableNo Data Beta2.66 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:KRRO) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Korro Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Korro Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.